CSIMarket
 
Surmodics Inc   (NASDAQ: SRDX)
Other Ticker:  
 
 
Price: $28.3000 $-0.02 -0.071%
Day's High: $28.61 Week Perf: 1.22 %
Day's Low: $ 27.67 30 Day Perf: -16.4 %
Volume (M): 104 52 Wk High: $ 42.44
Volume (M$): $ 2,935 52 Wk Avg: $36.85
Open: $28.08 52 Wk Low: $25.17



 Market Capitalization (Millions $) 403
 Shares Outstanding (Millions) 14
 Employees 389
 Revenues (TTM) (Millions $) 123
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) -23
 Capital Exp. (TTM) (Millions $) 3

Surmodics Inc
Surmodics Inc is a medical technology company that designs, manufactures, and markets a range of products focused on enhancing the performance of medical devices. Founded in 1979 and headquartered in Eden Prairie, Minnesota, the company has its presence in more than 80 countries worldwide. Surmodics works closely with its customers and partners to develop innovative solutions to address the critical needs in the medical community.

The company's product portfolio includes surface modification coatings, drug delivery coatings, hydrophilic coatings, antimicrobial coatings, and other related technologies. These coatings are designed to improve the performance of medical devices, such as catheters, stents, drug-eluting balloons, and diagnostic systems. Surmodics' products are used in a wide range of medical specialties, including cardiology, ophthalmology, and neurology.

Surmodics operates through two business segments: Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment involves developing, manufacturing, and selling medical device technologies, while the IVD segment involves developing, manufacturing, and selling diagnostic tests and equipment. While the Medical Device segment constitutes the majority of the company's revenue, the IVD segment offers healthy growth opportunities for the future.

Surmodics is known for its research and development capabilities, and the company invests heavily in R&D to develop new products and technologies. The company has a dedicated team of scientists and engineers who work on new ideas and projects that can be commercialized into innovative, market-leading products. The company also collaborates with leading medical device companies and academic institutions to advance its research and development capabilities.

One of Surmodics' key strengths lies in its ability to provide customized solutions to customers. The company offers co-development services, where it collaborates with customers to design and develop products that meet their specific needs. Additionally, Surmodics' experienced sales and marketing team works closely with customers to identify new market opportunities and develop customized marketing strategies.

The company's financials are strong, with steady revenue growth and profitability. The company generates the majority of its revenue from the United States, but it has a growing international presence. Surmodics' conservative balance sheet and low debt make it well-positioned to invest in new products and opportunities.

In conclusion, Surmodics Inc is a medical technology company that specializes in developing, manufacturing, and selling products that enhance the performance of medical devices. With a strong focus on R&D, market-leading products, and customer collaboration, Surmodics is well positioned to continue its growth and success in the medical technology industry.


   Company Address: 9924 West 74th Street Eden Prairie 55344 MN
   Company Phone Number: 500-7000   Stock Exchange / Ticker: NASDAQ SRDX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BAX   -5.39%    
BSX        3.22% 
EW        1.11% 
IART   -1.15%    
LIVN        6% 
MDT   -0.78%    
• View Complete Report
   



Business Update

Surmodics Gains FDA Approval for Pounce XL Thrombectomy System Amid Financial Challenges

Published Tue, Oct 1 2024 11:47 AM UTC

In a significant advancement for vascular intervention, Surmodics, Inc., a prominent player in the medical device and in vitro diagnostic technology sector, has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Pounce XL Thrombectomy System. This new device is designed for the non-surgical removal of thrombi and emboli from per...

Business Update

Surmodics Navigates a Dynamic Fiscal Landscape Analyzing Third Quarter Results and Future Prospects

Published Wed, Jul 31 2024 1:47 PM UTC

In a landscape that demands agility and foresight, Surmodics, Inc. (Nasdaq: SRDX), headquartered in Eden Prairie, Minnesota, finds itself at a pivotal junction as it reports its financial results for the third quarter of fiscal year 2024, alongside previously released metrics for the second quarter. As a prominent entity in the medical device and in vitro diagnostics sector,...

Business Update

Surmodics Partners with Premier Inc. to Revolutionize Thrombectomy Health Solutions Starting June 2024...

Published Mon, Jun 10 2024 1:08 PM UTC

Eden Prairie, Minn. - Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, has announced a significant achievement in the healthcare sector. The company has been awarded a group purchasing agreement for its innovative thrombectomy products with Premier, Inc. The agreement is set to take effect on June 1, 2024. Premier, In...

Business Update

Surmodics Showcases Impressive Rise in Total Revenue, Reveals Promising Fiscal Year Outlook Amid Sustained Healthcare Innovation

Published Wed, May 1 2024 11:47 AM UTC

Distinguished in the healthcare industry for their continuous innovation, Surmodics, Inc., headquartered in Eden Prairie, Minnesota, reported total revenue of $32.0 million for the second quarter of the fiscal year 2024, showcasing an outstanding 18% increase on a year-to-year basis. This remarkable growth becomes even more noteworthy when considering total revenue excluding...

Product Service News

Surmodics Shines at VEITH Symposium: Positive Trial Data and Steady Growth Chart the Path to Success

Published Thu, Nov 16 2023 12:30 PM UTC



Surmodics, a renowned provider of medical device and in vitro diagnostic technologies, recently presented the noteworthy 24-month data from the SWING Trial at the prestigious 50th annual VEITH Symposium in New York. The trial evaluated the safety and performance of the Sundance Sirolimus Drug-Coated Balloon (DCB), marking an important milestone in the healthcare in...







Surmodics Inc's Segments
Product Sales    55.3 % of total Revenue
Royalties    35.54 % of total Revenue
Research Development and Other    9.16 % of total Revenue
Medical Device    77.81 % of total Revenue
Medical Device Product Sales    33.81 % of total Revenue
Medical Device Royalties Performance Coatings    31.36 % of total Revenue
Medical Device License Fees    4.18 % of total Revenue
Medical Device Research Development and Other    8.46 % of total Revenue
In Vitro Diagnostics    22.19 % of total Revenue
In Vitro Diagnostics Product Sales    21.5 % of total Revenue
In Vitro Diagnostics Research Development and Other    0.7 % of total Revenue

  Surmodics Inc Outlook

On May 1 2024 the Surmodics Inc provided following guidance

Surmodics Inc., a renowned provider of cutting-edge medical device and in vitro diagnostic technologies, recently released their financial results for the second quarter of fiscal year 2024. The company reported a total revenue of $32.0 million, marking an impressive 18% increase compared to the previous year. This growth in revenue was attributed to various factors contributing to the company's success in the healthcare industry.

It is worth noting that the total revenue figure mentioned above excludes the revenue generated from Surmodics' SurVeil drug-coated balloon (DCB) product. This exclusion was done to provide a clearer picture of the company's overall financial performance, sans the potentiall...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com